To include your compound in the COVID-19 Resource Center, submit it here.

Novartis, UC Berkeley form center to study undruggable targets

Novartis AG (NYSE:NVS; SIX:NOVN) and its Novartis Institutes for Biomedical Research (NIBR) partnered with the University of California Berkeley to discover therapies against “undruggable” targets in infectious disease and cancer. As part of the collaboration, the partners will form the Novartis-Berkeley Center for Proteomics and Chemistry Technologies.

The deal

Read the full 484 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers